Health Canada consultation on proposed vaping products promotion regulations
https://policybase.cma.ca/link/policy14128

POLICY TYPE
Response to consultation

DATE
2020-01-20

TOPICS
Health care and patient safety
Population health, health equity, public health

Documents

CMA response:
HEALTH CANADA CONSULTATION ON PROPOSED VAPING PRODUCTS PROMOTION REGULATIONS
January 20, 2020
Health Canada consultation on vaping products labelling and packaging regulations
https://policybase.cma.ca/link/policy14124

POLICY TYPE  Response to consultation
DATE          2019-09-05
TOPICS        Health care and patient safety
              Population health, health equity, public health

Documents

CMA response:

HEALTH CANADA CONSULTATION
ON VAPING PRODUCTS
LABELLING AND PACKAGING
REGULATIONS

September 5, 2019
Health Canada consultation on potential market for cannabis health products that would not require practitioner oversight

https://policybase.cma.ca/link/policy14125

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Response to consultation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2019-09-03</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Health care and patient safety</td>
</tr>
<tr>
<td></td>
<td>Population health, health equity, public health</td>
</tr>
</tbody>
</table>

Documents
Health Canada consultation on the impact of vaping products advertising on youth and non-users of tobacco products
https://policybase.cma.ca/link/policy14022

POLICY TYPE Response to consultation
DATE 2019-03-22
TOPICS Health care and patient safety
Population health, health equity, public health

Documents
Health Canada’s consultation on new health-related labelling for tobacco products
https://policybase.cma.ca/link/policy13939

POLICY TYPE            Response to consultation
DATE                  2018-12-14
TOPICS                Health care and patient safety
Population health, health equity, public health

Documents
# Implementation of National Pharmacare

[https://policybase.cma.ca/link/policy13933](https://policybase.cma.ca/link/policy13933)

<table>
<thead>
<tr>
<th>Policy Type</th>
<th>Response to consultation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date</td>
<td>2018-10-02</td>
</tr>
<tr>
<td>Topics</td>
<td>Health care and patient safety, Pharmaceuticals, prescribing, cannabis, drugs</td>
</tr>
</tbody>
</table>

## Documents

![CMA submission: IMPLEMENTATION OF NATIONAL PHARMACARE](image)
Health Canada consultation on tobacco products regulations (plain and standardized appearance)
https://policybase.cma.ca/link/policy13930

POLICY TYPE
Response to consultation

DATE
2018-09-06

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on proposed front-of-package labelling
https://policybase.cma.ca/link/policy13882

Policy Type: Response to consultation
Date: 2018-04-23
Topics: Health care and patient safety, Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on the renewal of Federal Tobacco Control Strategy
https://policybase.cma.ca/link/policy13804

POLICY TYPE  Response to consultation
DATE        2017-04-05
TOPICS      Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Regulation of Self-Care Products in Canada

https://policybase.cma.ca/link/policy13802

POLICY TYPE  Response to consultation
DATE  2016-10-31
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
  Health care and patient safety

Documents
Health Canada’s Consultation on “Plain and Standardized Packaging”
https://policybase.cma.ca/link/policy13817

POLICY TYPE: Response to consultation
DATE: 2016-08-12
TOPICS: Health care and patient safety, Pharmaceuticals, prescribing, cannabis, drugs

Documents

August 17, 2016

Dear [Recipient],

The Canadian Medical Association (CMA) is pleased to provide the following submission in response to Health Canada’s Consultation on Plain and Standardized Packaging (the “consultation”). CMA is a national, non-profit, member-based organization established in 1867. It is Canada’s oldest and largest national medical association. Our mission is to enhance the overall health of Canadians through leadership in medicine and the health system.

CMA’s vision is to ensure that all Canadians have access to high-quality health care within a strong, publicly funded health care system. To achieve this vision, we advocate for policies and initiatives that promote and protect the health and well-being of all Canadians.

CMA supports Health Canada’s consultation on plain and standardized packaging as a measure to reduce the risk of medication errors and improve patient safety. The consultation is an important opportunity to consider the potential benefits and costs of plain and standardized packaging, as well as to hear from stakeholders across various sectors.

CMA submits the following recommendations in response to the consultation:

1. Plain and standardized packaging should be mandatory for all prescription medications.

2. Plain and standardized packaging should include the following information:
   - Product name
   - Dosage
   - Quantity
   - Manufacturer
   - Date of manufacture

3. Plain and standardized packaging should be designed to be easily readable and understandable by patients.

4. Plain and standardized packaging should be cost-effective and should not increase the cost of healthcare.

5. Plain and standardized packaging should be phased in over a period of time to allow for adequate planning and preparation by healthcare providers and pharmaceutical companies.

6. Plain and standardized packaging should be accompanied by patient education materials to ensure that patients understand how to use the packaging.

7. Plain and standardized packaging should be supported by ongoing monitoring and evaluation to assess its impact on patient safety and healthcare outcomes.

CMA acknowledges that implementing plain and standardized packaging will require significant resources and efforts. However, we believe that the potential benefits in terms of reducing medication errors and improving patient safety justify the investment.

CMA recommends that Health Canada considers the following measures to support the implementation of plain and standardized packaging:

1. Provide funding for the development and implementation of plain and standardized packaging.

2. Provide resources and support to healthcare providers to ensure they are adequately prepared for the transition.

3. Establish a monitoring and evaluation framework to track the impact of plain and standardized packaging on patient safety.

4. Engage with stakeholders to ensure that all perspectives are considered.

CMA remains committed to advancing the health and well-being of all Canadians and welcomes the opportunity to contribute to the consultation on plain and standardized packaging.

Sincerely,

[Your Name]
[Position]
[Organization]
Regulatory framework for the mandatory reporting of adverse drug reactions and medical device incidents by provincial and territorial healthcare institutions.

https://policybase.cma.ca/link/policy11814

POLICY TYPE: Response to consultation

DATE: 2016-01-20

TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Health care and patient safety

Documents
Tamper Resistance under the Controlled Drugs and Substances Act
https://policybase.cma.ca/link/policy11295

POLICY TYPE
Response to consultation

DATE
2014-08-26

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs